Clarithromycin Solid Lipid Nanoparticles for Topical Ocular Therapy: Optimization, Evaluation, and In Vivo Studies.

MLA

Nair, Anroop B., et al. “Clarithromycin Solid Lipid Nanoparticles for Topical Ocular Therapy: Optimization, Evaluation, and In Vivo Studies.” Pharmaceutics, vol. 13, no. 4, Apr. 2021, p. 523. EBSCOhost, https://doi.org/10.3390/pharmaceutics13040523.

APA

Nair, A. B., Shah, J., Al-Dhubiab, B. E., Jacob, S., Patel, S. S., Venugopala, K. N., Morsy, M. A., Gupta, S., Attimarad, M., Sreeharsha, N., Shinu, P., Silva, A. C., & Lobo, J. M. S. (2021). Clarithromycin Solid Lipid Nanoparticles for Topical Ocular Therapy: Optimization, Evaluation, and In Vivo Studies. Pharmaceutics, 13(4), 523. https://doi.org/10.3390/pharmaceutics13040523

Chicago

Nair, Anroop B., Jigar Shah, Bandar E. Al-Dhubiab, Shery Jacob, Snehal S. Patel, Katharigatta N. Venugopala, Mohamed A. Morsy, et al. 2021. “Clarithromycin Solid Lipid Nanoparticles for Topical Ocular Therapy: Optimization, Evaluation, and In Vivo Studies.” Pharmaceutics 13 (4): 523. doi:10.3390/pharmaceutics13040523.